Danaher Corp /de/ (DHR) · Oct 20, 2026 · Earnings
Beat — Adjusted EPS $2.11 vs ~$1.92 consensus
Danaher’s Q3 earnings beat expectations and full-year EPS guidance rose, but respiratory testing and Diagnostics remain important offsets.
Danaher is moving through a post-Masimo integration phase while trying to revive underlying growth across life sciences and diagnostics; Julie Sawyer Montgomery also became CEO on October 1, 2026. Masimo was acquired for approximately $9.8 billion, and management has positioned the deal as a way to broaden Danaher’s diagnostics platform. The quarter cleared the main earnings hurdle. Adjusted diluted EPS was $2.11 versus a published consensus near $1.92, while sales of $6.554 billion were essentially in line with the roughly $6.56 billion estimate. The EPS outperformance is therefore the cleanest positive surprise, rather than a broad revenue blowout. 〔0〕
| Metric | Q3 2026 | Q3 2025 | Year-over-year change | Expectation / comparison |
|---|---|---|---|---|
| Sales | $6.554B | $6.053B | +8.5% | ~$6.56B consensus |
| Adjusted diluted EPS | $2.11 | $1.89 | +11.6% | ~$1.92 consensus |
| Core sales growth | 3.0% | — | — | Excluding respiratory: 5.5% |
| Free cash flow | $1.632B | $1.370B | +19.0% | Stronger cash generation |
| FY2026 adjusted EPS guidance | $8.57–$8.62 | — | — | Raised from $8.45–$8.60 |
The underlying business is improving, but the headline growth needs adjustment. Core sales excluding respiratory testing accelerated to 5.5%, up from 4.5% in the June quarter, with Biotechnology at 7.0% and Life Sciences at 4.5%. That supports the company’s recovery narrative, although total core growth was only 3.0% and Diagnostics core growth was just 0.5%; the 17.0% GAAP Diagnostics increase was heavily affected by acquisition and respiratory-testing comparisons. 〔1〕
Management raised the earnings outlook, making this more than a routine beat. Full-year adjusted EPS guidance moved to $8.57–$8.62 from the prior $8.45–$8.60 range, while fourth-quarter core growth excluding respiratory testing is expected at 4.0%–5.0%. The company still expects respiratory revenue to reduce fourth-quarter core growth by roughly 150 basis points, so the improvement is coming from the underlying franchises rather than a renewed testing surge. 〔2〕
Cash generation reinforces the operational improvement, though reported EPS includes a tax tailwind. Free cash flow rose 19% to $1.632 billion, but the quarter also benefited from $263 million of discrete tax benefits tied mainly to audit settlements. That makes the adjusted EPS beat more informative than GAAP EPS, but it also means the reported profit increase was not entirely operational.
Bottom line: This was a genuine step forward: EPS beat, cash flow was strong, and full-year guidance rose as core demand improved beyond respiratory testing. The signal is positive, but the recovery is still uneven because Diagnostics remains soft underneath acquisition and testing-related comparisons.
StatLab acquisition close, expected by year-end 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!